An Orthotopic Xenograft Model for Preclinical Evaluation of CAR T Cell Therapy in Glioblastoma.
- 1Chair of Cellular Immunotherapy, Department of Medicine II, University Hospital Würzburg, Würzburg, Germany.
- 2Department of Neurology, University Hospital Würzburg, Würzburg, Germany.
- 3Department of Medicine II, University Hospital Würzburg, Würzburg, Germany.
Abstract
Glioblastoma (GBM) is the most lethal primary brain tumor in adults, and despite intensive research efforts, effective therapeutic breakthroughs remain elusive. Consequently, the standard of care has remained largely unchanged for nearly 30 years, underscoring the need for robust preclinical models to evaluate experimental therapies. One particularly promising approach is chimeric antigen receptor (CAR) T cell therapy, which has demonstrated remarkable success in several hematologic malignancies but has not yet achieved comparable efficacy in solid tumors. This article describes the generation of orthotopic GBM xenografts in NSG mice, including anesthesia, surgical procedures, and postoperative care, followed by locoregional delivery of human CAR T cells into the lateral ventricle and subsequent assessment of therapeutic efficacy. Together, these protocols provide a reliable platform for evaluating GBM-directed CAR T cell therapies in both basic and translational research. © 2026 The Author(s). Current Protocols published by Wiley Periodicals LLC. Basic Protocol 1: Intracranial tumor implantation Basic Protocol 2: Intraventricular CAR T cell administration Support Protocol 1: Bioluminescence imaging of xenografts Support Protocol 2: Endpoint analysis of residual tumor burden by flow cytometry.
Related
- Optimization of a Subcutaneous Epithelioid Hemangioendothelioma Xenograft Model for Evaluation of Preclinical Therapeutics
- Development of an Orthotopic Patient-Derived Xenograft Model of Gastro-Esophageal Adenocarcinoma: A Single-Lineage Pilot Study
- Advanced machine learning strategies for predicting therapy response in preclinical glioblastoma using longitudinal MRI
- Cytokine-induced killer cells combined with temozolomide suppress glioblastoma progression in an orthotopic model and demonstrate clinical feasibility in recurrent glioblastoma
- Indole analogs and the aryl sulfonamide AqB011 potently restrain the invasiveness of glioblastoma cells, as determined in ex vivo xenograft tissue slice co-cultures (XTCCs).
BibTeX
@article{hubner2026orthotopic,
title = {{An Orthotopic Xenograft Model for Preclinical Evaluation of CAR T Cell Therapy in Glioblastoma.}},
author = {Julian Hübner and Rhonda McFleder and Chi Wang Ip and Miriam Alb and Hermann Einsele and Michael Hudecek and Thomas Nerreter},
journal = {Current protocols},
year = {2026},
month = oct,
doi = {10.1002/cpz1.70503},
url = {https://europepmc.org/article/MED/42961140},
note = {CC BY},
}
RIS
TY - JOUR
TI - An Orthotopic Xenograft Model for Preclinical Evaluation of CAR T Cell Therapy in Glioblastoma.
AU - Julian Hübner
AU - Rhonda McFleder
AU - Chi Wang Ip
AU - Miriam Alb
AU - Hermann Einsele
AU - Michael Hudecek
AU - Thomas Nerreter
PY - 2026
DA - 2026/10/30
JO - Current protocols
DO - 10.1002/cpz1.70503
UR - https://europepmc.org/article/MED/42961140
AB - Glioblastoma (GBM) is the most lethal primary brain tumor in adults, and despite intensive research efforts, effective therapeutic breakthroughs remain elusive. Consequently, the standard of care has remained largely unchanged for nearly 30 years, underscoring the need for robust preclinical models to evaluate experimental therapies. One particularly promising approach is chimeric antigen receptor (CAR) T cell therapy, which has demonstrated remarkable success in several hematologic malignancies but has not yet achieved comparable efficacy in solid tumors. This article describes the generation of orthotopic GBM xenografts in NSG mice, including anesthesia, surgical procedures, and postoperative care, followed by locoregional delivery of human CAR T cells into the lateral ventricle and subsequent assessment of therapeutic efficacy. Together, these protocols provide a reliable platform for evaluating GBM-directed CAR T cell therapies in both basic and translational research. © 2026 The Author(s). Current Protocols published by Wiley Periodicals LLC. Basic Protocol 1: Intracranial tumor implantation Basic Protocol 2: Intraventricular CAR T cell administration Support Protocol 1: Bioluminescence imaging of xenografts Support Protocol 2: Endpoint analysis of residual tumor burden by flow cytometry.
SN - 2691-1299
ER -